{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:55:36Z","timestamp":1781844936627,"version":"3.54.5"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>The duration of anticoagulation in patients with catheter- related thrombosis (CRT) is not standardized. This is a multiinstitutional prospective pilot study in patients with cancer and upper extremity CRT. Patients received therapeutic enoxaparin for 1\u200amonth after catheter removal. Incidence of recurrent thrombosis, hemorrhage, and postthrombotic syndrome (PTS) using the modified Villalta scale, and functional limitation using the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire were assessed at months 1, 3, and 6 after catheter removal. Clopper\u2013Pearson exact 95% confidence intervals (CI), Pearson correlations, and Skillings-Mack, and Wilcoxon signed ranks tests were done. Twenty-seven patients from three institutions were enrolled. Feasibility outcomes were not met. Seventy percent (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a19) of the cohort had hematologic malignancies. Excluding two patients who were still on enoxaparin at study withdrawal, the median total duration of therapeutic enoxaparin was 32 [interquartile range (IQR) 30\u201352] days in the remaining 25 patients. During the 6\u200amonths after catheter removal, the incidence of recurrent thrombosis was 0% (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a0\/20, 95% CI 0\u201317%) and major hemorrhage was 5% (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a1\/20, 95% CI 0.13\u201325%). One patient (5%, 95% CI 0.13\u201325%) had PTS in the affected arm at any visit, and none had severe PTS. Higher PTS scores were associated with higher DASH scores. DASH scores at month 6 were significantly lower compared with month 1 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.0066). No deaths occurred. A multicenter pilot study of treatment with anticoagulation for 1\u200amonth after catheter removal did not meet feasibility outcomes but we found no recurrent thrombosis and a low incidence of PTS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mbc.0000000000001122","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T08:01:17Z","timestamp":1641283277000},"page":"171-175","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1\u200amonth of anticoagulation after catheter removal"],"prefix":"10.1097","volume":"33","author":[{"given":"Lisa","family":"Baumann Kreuziger","sequence":"first","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin; Blood Research Institute, Versiti, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingen","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin; Blood Research Institute, Versiti, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Bartosic","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pippa","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin; Blood Research Institute, Versiti, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"R1-20250617","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMra011883","article-title":"Preventing complications of central venous catheterization","volume":"348","author":"McGee","year":"2003","journal-title":"New Engl J Med"},{"key":"R2-20250617","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/j.1538-7836.2012.04817.x","article-title":"Epidemiology and prevention of catheter-related thrombosis in patients with cancer","volume":"10","author":"Lee","year":"2012","journal-title":"J Thromb Haemost"},{"key":"R3-20250617","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(13)60592-9","article-title":"Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis","volume":"382","author":"Chopra","year":"2013","journal-title":"Lancet"},{"key":"R4-20250617","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMcp1008740","article-title":"Clinical practice. Deep-vein thrombosis ofthe upper extremities","volume":"364","author":"Kucher","year":"2011","journal-title":"New Engl J Med"},{"key":"R5-20250617","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1055\/s-0038-1648912","article-title":"Pulmonary embolism in patients with upper extremity DVT associated to venous central lines-a prospective study","volume":"72","author":"Monreal","year":"1994","journal-title":"Thromb Haemost"},{"key":"R6-20250617","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer I. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-20250617","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"R8-20250617","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer- associated venous thromboembolism","volume":"378","author":"Raskob","year":"2017","journal-title":"N Engl J Med"},{"key":"R9-20250617","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"R10-20250617","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"R11-20250617","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"key":"R12-20250617","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"R13-20250617","first-page":"1181","article-title":"Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Streiff","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R14-20250617","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1002\/ajh.24588","article-title":"Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban","volume":"92","author":"Laube","year":"2017","journal-title":"Am J Hematol"},{"key":"R15-20250617","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2017.04.003","article-title":"A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)","volume":"162","author":"Davies","year":"2018","journal-title":"Thromb Res"},{"issue":"(2 Suppl)","key":"R16-20250617","first-page":"e419S-94S","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"R17-20250617","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jth.12071","article-title":"International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer","volume":"11","author":"Debourdeau","year":"2013","journal-title":"J Thromb Haemost"},{"key":"R18-20250617","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.thromres.2015.08.020","article-title":"Systematic review of anticoagulant treatment of catheter-related thrombosis","volume":"136","author":"Baumann Kreuziger","year":"2015","journal-title":"Thromb Res"},{"key":"R19-20250617","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.thromres.2021.03.021","article-title":"Treatment of catheter-related thrombosis in patients with hematologic malignancies: a Venous thromboEmbolism Network U.S. retrospective cohort study","volume":"202","author":"Baumann Kreuziger","year":"2021","journal-title":"Thromb Res"},{"key":"R20-20250617","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"R21-20250617","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"R22-20250617","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1160\/TH04-10-0640","article-title":"Postthrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adults","volume":"93","author":"Kahn","year":"2005","journal-title":"Thromb Haemost"},{"key":"R23-20250617","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.thromres.2005.05.029","article-title":"The postthrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review","volume":"117","author":"Elman","year":"2006","journal-title":"Thromb Res"},{"key":"R24-20250617","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1538-7836.2008.02998.x","article-title":"Comparison between idiopathic deep vein thrombosis of the upper and lower extremity regarding risk factors and recurrence","volume":"6","author":"Lechner","year":"2008","journal-title":"J Thromb Haemost"}],"container-title":["Blood Coagulation &amp; Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MBC.0000000000001122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T23:07:36Z","timestamp":1750201656000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MBC.0000000000001122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0000000000001122","relation":{},"ISSN":["0957-5235","1473-5733"],"issn-type":[{"value":"0957-5235","type":"print"},{"value":"1473-5733","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]}}}